Companies / VTRS vs ABT
VTRS vs ABT: Viatris and Abbott Laboratories
Viatris (VTRS) reported $14.3B in revenue against a -24.6% net margin, while Abbott Laboratories (ABT) reported $44.3B at a 14.7% net margin, most recently.
| Metric | VTRS | ABT |
|---|---|---|
| Revenue | $14.3B | $44.3B |
| Net Income | $-3.5B | $6.5B |
| Gross Margin | 35.1% | 56.4% |
| Operating Margin | -18.6% | 18.2% |
| EPS (Diluted) | $-3.00 | $3.72 |
| Free Cash Flow | $1.9B | $7.4B |
| Total Debt | $14.4B | $12.9B |
| P/E Ratio | n/m | 33.7× |
| P/B Ratio | n/m | n/m |
| Stock Price | $19.00 | $112.71 |
Free: last 5 years
| Fiscal year | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| VTRS Revenue | ••••• | ••••• | ••••• | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| ABT Revenue | ••••• | ••••• | ••••• | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |